Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC

Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC

Introduction: Subcutaneous (SC) atezolizumab, a co-formulation containing atezolizumab and recombinant human hyaluronidase PH20), has been approved for use in more than 50 countries for the same indications as intravenous (IV) atezolizumab. IMscin002 (NCT05171777), a phase 2, randomized, open-label,...

Full description

Saved in:
Bibliographic Details
Main Authors: Federico Cappuzzo, MD, Zanete Zvirbule, MD, Ernesto Korbenfeld, MD, Jaroslaw Kolb-Sielecki, MD, Dolores Isla, MD, PhD, Aleksandra Szczesna, MD, PhD, Amparo Yovanna Castro Sanchez, PhD, Alberto Bustillos, MD, Xiaoyan Liu, PhD, Fiona Young, MbChB, Nadia Tosti, PhD, Marta Freitas Monteiro, MSc, PhD, Margarita Majem, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JTO Clinical and Research Reports
Subjects:
IMscin002
Atezolizumab
Subcutaneous
Intravenous
Patient preferences
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000311
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items